PHARMARON (03759.HK): shareholder transfer priced at RMB 38.89/share
- The inquiry received 51 valid quotation forms covering fund managers, qualified foreign institutional investors, securities firms, insurers and private fund managers.
- The transfer does not involve a change of control of PHARMARON or affect its governance structure or continuing operations.
NewTimeSpace News: On 12 October 2026, Pharmaron Beijing Co., Ltd. (stock code: 03759.HK) published an overseas regulatory announcement on a shareholder inquiry-based share transfer filed with the Shenzhen Stock Exchange. The preliminary transfer price is RMB 38.89 per share. The transfer is a non-public transfer not conducted through centralised bidding, and the shares acquired may not be transferred within six months.
The inquiry received 51 valid quotation forms covering fund managers, qualified foreign institutional investors, securities firms, insurers and private fund managers, representing 61,000,000 shares validly subscribed, 3.32 times the offer. The shares were fully subscribed, with 13 institutional investors preliminarily identified as transferees for 18,373,000 shares. The transfer does not involve a change of control or affect the Company's governance or continuing operations.
- PHARMARON(03759.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 750.19 million, YoY increase of 6.96%
- Pharmaron (03759.HK): Shareholders' Reduction Plan Completed, Total Reduction of 1.50%
- PHARMARON (03759.HK): Completes H-Share Placement, Net Proceeds Approximately HK$1.319 Billion
